


Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 2

**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**  
(Amendments are illustrated by showing deletions by ~~striketrough~~ or by [[double brackets]] for deletions of five or fewer characters and additions by underlining)

Claims 1-17 (canceled)

Claim 18 (currently amended): A compound of the  
formula:



wherein

A<sup>1</sup> is a D- or L-isomer of an aromatic amino acid or is  
deleted;

A<sup>3</sup> is an aromatic amino acid;

A<sup>6</sup> is Thr, Thr(Bzl), Gly, Ser, an Eaa or an aliphatic amino  
acid;

A<sup>8</sup> is a D- or L-isomer selected from the group consisting of  
Thr, Ser, an aromatic amino acid or an aliphatic amino acid;

each of R<sub>1</sub> and R<sub>2</sub>, is, independently, H or substituted or  
unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle,  
heterocycle lower alkyl, E<sub>1</sub>SO<sub>2</sub> or E<sub>1</sub>CO wherein E<sub>1</sub> is aryl, aryl  
lower alkyl, heterocycle or heterocycle lower alky and said  
substituent is halo, lower alkyl, hydroxy, halo lower alkyl or  
hydroxy lower alkyl; and

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 3

---

$R_3[[,]]$  is OH,  $NH_2$ ,  $C_{1-12}$  alkoxy or  $NH-Y-CH_2-Z$ , wherein Y is a  $C_{1-12}$  hydrocarbon moiety and Z is H, OH,  $CO_2H$  or  $CONH_2$ .

provided that  $R_{3L}$  together with the carbonyl group of  $A^8$  attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

further provided that a disulfide bond links the sidechains of  $A^2$  and  $A^7$ ; and

further provided that if  $A^1$  is D-Phe or p- $NO_2$ -Phe,  $A^3$  is Phe or Tyr and  $A^6$  is Thr or Val, then  $A^8$  is  $\beta$ -Nal.

19 (currently amended): A compound of claim ~~18~~ 44, wherein  $A^1$  is the D- or L-isomer of  $\beta$ -Nal, o-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , p-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , m-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ ,  $F_5$ -Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal;  $A^3$  is  $\beta$ -Nal, o-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , p-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , m-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ ,  $F_5$ -Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal;  $A^6$  is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle,  $\beta$ -Ala, Gaba, or Val; and  $A^8$  is the D- or L-isomer of Thr, Dip,  $F_5$ -Phe, p-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , o-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , m-X-Phe wherein X is H, OH,  $CH_3$ , halo,  $OCH_3$ ,  $NH_2$ , CN, or  $NO_2$ , Igl, Tyr(Bzl), or  $\beta$ -Nal.

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 4

---

20 (currently amended): A compound of claim 19, wherein A<sup>1</sup> is the D- or L-isomer of  $\beta$ -Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe; A<sup>3</sup> is Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup> is p-F-Phe,  $\beta$ -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperazineethanesulfonyl; and R<sub>2</sub> is H, ~~and R<sub>3</sub>, together with the carboxy group of A<sup>8</sup> attached thereto, are reduced to form H or CH<sub>3</sub>OH.~~

21 (original): A compound of claim 20, wherein A<sup>3</sup> is Pal.

22 (previously presented): A compound of claim 19, of the formula:

H<sub>2</sub>- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH<sub>3</sub>CO)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 5

---

(H) (CH<sub>3</sub>CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

(H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

(H) (CH<sub>3</sub>CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxymethyl) propylamide;

(H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

(H) (CH<sub>3</sub>CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 6

---

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H(CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 7

---

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H<sub>2</sub>- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH<sub>3</sub>CO)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH<sub>3</sub>CO)- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 9

(H) (CH<sub>3</sub>CO) Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;

(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;

(H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;

H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

(H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

(H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

(H) (CH<sub>3</sub>CO) Phe-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

(H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;

H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-naphthyl) ethylamide;

H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-naphthyl) ethylamide;

H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys- (2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide; or


Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 10

---

H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R,3R-(2-hydroxymethyl)-  
3-hydroxy)propylamide;

or a pharmaceutically acceptable salt thereof.

23 (currently amended): A compound of the formula:



wherein

A<sup>1</sup> is a D- or L-isomer of an aromatic amino acid, or is  
deleted;

A<sup>2</sup> is a D-aromatic amino acid ~~or a D-aliphatic amino acid~~,

A<sup>3</sup> is an aromatic amino acid;

A<sup>6</sup> is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino  
acid;

A<sup>7</sup> is an aromatic amino acid or an aliphatic amino acid;

A<sup>8</sup> is a D- or L-isomer selected from the group consisting of  
Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R<sub>1</sub> and R<sub>2</sub>, is, independently, H or substituted or  
unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle,  
heterocycle lower alkyl, E<sub>1</sub>SO<sub>2</sub> or E<sub>1</sub>CO wherein E<sub>1</sub> is aryl, aryl  
lower alkyl, heterocycle, or heterocycle lower alky and said  
substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or  
hydroxy lower alkyl; and

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 11

---

R<sub>3</sub> is OH, NH<sub>2</sub>, C<sub>1-12</sub> alkoxy, or NH-Y-CH<sub>2</sub>-Z, wherein Y is a C<sub>1-12</sub> hydrocarbon moiety and Z is H, OH, CO<sub>2</sub>H, or CONH<sub>2</sub>, or R<sub>3</sub>, together with the carbonyl group of A<sup>8</sup> attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

~~provided if A<sup>2</sup> is D Cys or D Pen and A<sup>7</sup> is Cys or Pen, then a disulfide bond links the sidechains of A<sup>2</sup> and A<sup>7</sup>, and~~

~~further provided that if A<sup>1</sup> is D Phe or p-NO<sub>2</sub>-Phe, A<sup>2</sup> is D-Cys, A<sup>3</sup> is Phe or Tyr, A<sup>6</sup> is Thr or Val and A<sup>7</sup> is Cys, then A<sup>8</sup> is β-Nal.~~

24 (previously presented): A compound of claim 23, wherein A<sup>1</sup> is an L- amino acid and A<sup>2</sup> is a D-aromatic amino acid.

25 (previously presented): A compound of claim 24, wherein each of A<sup>1</sup>, A<sup>3</sup>, and A<sup>7</sup>, is, independently, β-Nal, o-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN or NO<sub>2</sub>, p-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN or NO<sub>2</sub>, m-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>2</sup> is D-β-Nal, D-o-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, D-p-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, D-m-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, D-F<sub>5</sub>-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba, or Val; and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, o-X-Phe wherein X is H,

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 12

---

OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, m-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, Igl, Tyr (Bzl), or β-Nal.

26 (previously presented): A compound of claim 25, wherein A<sup>1</sup> is β-Nal or Phe, A<sup>2</sup> is D-Cpa or D-Phe; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Abu, Thr, or Val; A<sup>7</sup> is Phe; and A<sup>8</sup> is Thr; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is NH<sub>2</sub>.

27 (previously presented): A compound of claim 25 of the formula:

H<sub>2</sub>-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
H<sub>2</sub>-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
H<sub>2</sub>-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
(H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
H<sub>2</sub>-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
(H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

(H) (CH<sub>3</sub>CO) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cpa -  
Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-  
Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

H<sub>2</sub>-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

(H) (CH<sub>3</sub>CO) -β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cpa-Pal-  
D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-  
Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;

(H) (CH<sub>3</sub>CO) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cpa -  
Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-  
Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;

H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or

H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>; or

a pharmaceutically acceptable salt thereof.

28 (original): A compound of claim 23, wherein A<sup>1</sup> is a  
D-amino acid and A<sup>2</sup> is a D-aromatic amino acid.

29 (previously presented): A compound of claim 28,  
wherein each of A<sup>1</sup> and A<sup>2</sup>, is, independently, D-β-Nal, D-o-X-Phe  
wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, D-p-X-Phe

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 14

---

wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, D-m-X-Phe  
wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, D-F<sub>5</sub>-Phe, D-  
Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta,  
D-Bip, D-Npa, or D-Pal; each of A<sup>3</sup> and A<sup>7</sup>, independently, is β-  
Nal, o-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>,  
p-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, m-X-  
Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, F<sub>5</sub>-Phe,  
Trp, Dip, 2-Pal, His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or  
Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle,  
β-Ala, Gaba, or Val; and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-  
Phe, p-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>,  
o-X-Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, m-X-  
Phe wherein X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>, Igl,  
Tyr(Bzl), or β-Nal.

30 (previously presented): A compound of claim 29,  
wherein A<sup>1</sup> is D-β-Nal or D-Phe; A<sup>2</sup> is D-Cpa or D-Phe; A<sup>3</sup> is Phe or  
Tyr; A<sup>6</sup> is Thr or Val; A<sup>7</sup> is Phe; A<sup>8</sup> is Thr; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-  
hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-  
piperizineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is NH<sub>2</sub>.

31 (previously presented): A compound of claim 29 of  
the formula:

H<sub>2</sub>-D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;

H<sub>2</sub>-D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;

H<sub>2</sub>-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;

H<sub>2</sub>-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 15

H<sub>2</sub>-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or  
a pharmaceutically acceptable salt thereof.

32 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

33 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

34 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

35 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

36 (previously presented): A method of imaging cells having somatostatin receptors which comprises administering to a

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 16

subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 18 having Tyr(I).

37 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

38 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

39 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

40 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

41 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound

Applicant : Coy *et al.*  
Serial No. : 10/712,081  
Filed : November 13, 2003  
Page : 17

---

according to claim 23 or a pharmaceutically acceptable salt thereof.

42 (previously presented): A method of imaging cells having somatostatin receptors which comprises administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 23 having Tyr(I).

43 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

44 (new): A compound of claim 18, wherein A<sup>8</sup> is a D- or L-isomer of Thr or  $\beta$ -Nal; and R<sub>3</sub>, together with A<sup>8</sup>, form (2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide or 2R-(2-naphthyl)ethylamide; or a pharmaceutically acceptable salt thereof.